FR2848452B1 - Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer - Google Patents

Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer

Info

Publication number
FR2848452B1
FR2848452B1 FR0215722A FR0215722A FR2848452B1 FR 2848452 B1 FR2848452 B1 FR 2848452B1 FR 0215722 A FR0215722 A FR 0215722A FR 0215722 A FR0215722 A FR 0215722A FR 2848452 B1 FR2848452 B1 FR 2848452B1
Authority
FR
France
Prior art keywords
alzheimer
intestinal
disease
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0215722A
Other languages
English (en)
French (fr)
Other versions
FR2848452A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0215722A priority Critical patent/FR2848452B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to ARP030104540A priority patent/AR042354A1/es
Priority to KR1020057010595A priority patent/KR20050084250A/ko
Priority to BR0317280-5A priority patent/BR0317280A/pt
Priority to NZ540496A priority patent/NZ540496A/en
Priority to PE2003001247A priority patent/PE20040770A1/es
Priority to CNA2003801059727A priority patent/CN1726016A/zh
Priority to EP03815109A priority patent/EP1572174A1/fr
Priority to PCT/FR2003/003654 priority patent/WO2004062652A1/fr
Priority to JP2004566119A priority patent/JP2006514063A/ja
Priority to CA002507945A priority patent/CA2507945A1/fr
Priority to AU2003296802A priority patent/AU2003296802A1/en
Priority to YUP-2005/0420A priority patent/RS20050420A/sr
Priority to PL377110A priority patent/PL377110A1/pl
Priority to MXPA05005556A priority patent/MXPA05005556A/es
Priority to RU2005121909/15A priority patent/RU2005121909A/ru
Priority to HR20050534A priority patent/HRP20050534A2/xx
Priority to TW092134949A priority patent/TW200503707A/zh
Priority to US10/734,787 priority patent/US20040138145A1/en
Publication of FR2848452A1 publication Critical patent/FR2848452A1/fr
Priority to ZA200504656A priority patent/ZA200504656B/en
Priority to CO05056010A priority patent/CO5700712A2/es
Priority to MA28329A priority patent/MA27500A1/fr
Priority to NO20053341A priority patent/NO20053341L/no
Application granted granted Critical
Publication of FR2848452B1 publication Critical patent/FR2848452B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
FR0215722A 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer Expired - Fee Related FR2848452B1 (fr)

Priority Applications (23)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
PL377110A PL377110A1 (pl) 2002-12-12 2003-12-10 Zapobieganie i leczenie choroby Alzheimera
BR0317280-5A BR0317280A (pt) 2002-12-12 2003-12-10 Prevenção e tratamento do mal de alzheimer
NZ540496A NZ540496A (en) 2002-12-12 2003-12-10 Prevention and treatment of alzheimer's disease
PE2003001247A PE20040770A1 (es) 2002-12-12 2003-12-10 Aplicacion de inhibidores de recaptura intestinal de acido biliar para la prevencion y el tratamiento de la enfermedad de alzheimer
CNA2003801059727A CN1726016A (zh) 2002-12-12 2003-12-10 阿尔茨海默氏病的预防和治疗
EP03815109A EP1572174A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d alzheimer
PCT/FR2003/003654 WO2004062652A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d'alzheimer
JP2004566119A JP2006514063A (ja) 2002-12-12 2003-12-10 アルツハイマー病の予防および治療
KR1020057010595A KR20050084250A (ko) 2002-12-12 2003-12-10 알츠하이머병의 예방 및 치료
AU2003296802A AU2003296802A1 (en) 2002-12-12 2003-12-10 Prevention and treatment of alzheimer's disease
RU2005121909/15A RU2005121909A (ru) 2002-12-12 2003-12-10 Профилактика и лечение болезни альцгеймера
ARP030104540A AR042354A1 (es) 2002-12-12 2003-12-10 Aplicacion de inhibidores de recaptura intestinal del acido biliar para la prevencion y el tratamiento de la enfermedad de alzheimer
MXPA05005556A MXPA05005556A (es) 2002-12-12 2003-12-10 Prevencion y tratamiento de la enfermedad de alzheimer.
YUP-2005/0420A RS20050420A (sr) 2002-12-12 2003-12-10 Prevencija i lečenje alzheimer-ove bolesti
HR20050534A HRP20050534A2 (en) 2002-12-12 2003-12-10 Prevention and treatment of alzheimer's disease
CA002507945A CA2507945A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d'alzheimer
TW092134949A TW200503707A (en) 2002-12-12 2003-12-11 Application of intestinal biliary acid reuptake inhibitors for the prevention and threatment of alzheimer's disease
US10/734,787 US20040138145A1 (en) 2002-12-12 2003-12-12 Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
ZA200504656A ZA200504656B (en) 2002-12-12 2005-06-07 Prevention and treatment of Alzheimer's disease
CO05056010A CO5700712A2 (es) 2002-12-12 2005-06-09 Prevencion y tratamiento de la enfermedad de alzheimer
MA28329A MA27500A1 (fr) 2002-12-12 2005-06-10 Prevention et traitement de la maladie d'alzheimer
NO20053341A NO20053341L (no) 2002-12-12 2005-07-08 Hindring og behandling av Alzheimers sykdom.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
FR2848452A1 FR2848452A1 (fr) 2004-06-18
FR2848452B1 true FR2848452B1 (fr) 2007-04-06

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0215722A Expired - Fee Related FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer

Country Status (22)

Country Link
EP (1) EP1572174A1 (https=)
JP (1) JP2006514063A (https=)
KR (1) KR20050084250A (https=)
CN (1) CN1726016A (https=)
AR (1) AR042354A1 (https=)
AU (1) AU2003296802A1 (https=)
BR (1) BR0317280A (https=)
CA (1) CA2507945A1 (https=)
CO (1) CO5700712A2 (https=)
FR (1) FR2848452B1 (https=)
HR (1) HRP20050534A2 (https=)
MA (1) MA27500A1 (https=)
MX (1) MXPA05005556A (https=)
NO (1) NO20053341L (https=)
NZ (1) NZ540496A (https=)
PE (1) PE20040770A1 (https=)
PL (1) PL377110A1 (https=)
RS (1) RS20050420A (https=)
RU (1) RU2005121909A (https=)
TW (1) TW200503707A (https=)
WO (1) WO2004062652A1 (https=)
ZA (1) ZA200504656B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
JP2008518955A (ja) 2004-11-02 2008-06-05 ノースウェスタン ユニバーシティ ピリダジン化合物および方法
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
KR101441725B1 (ko) * 2007-05-22 2014-09-18 오츠카 세이야쿠 가부시키가이샤 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) * 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
EP0572560B1 (en) * 1991-02-22 2003-01-29 SHAPIRO, Howard, K. Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
CA2258744A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
ATE320803T1 (de) * 1998-01-28 2006-04-15 Warner Lambert Co Verfahren zur behandlung von alzheimerschen krankheit
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
AU2001233299A1 (en) * 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
MXPA05005556A (es) 2005-07-26
BR0317280A (pt) 2005-11-08
PL377110A1 (pl) 2006-01-23
PE20040770A1 (es) 2004-12-10
CN1726016A (zh) 2006-01-25
FR2848452A1 (fr) 2004-06-18
WO2004062652A1 (fr) 2004-07-29
EP1572174A1 (fr) 2005-09-14
RU2005121909A (ru) 2006-01-20
RS20050420A (sr) 2007-04-10
ZA200504656B (en) 2006-08-30
JP2006514063A (ja) 2006-04-27
AR042354A1 (es) 2005-06-15
MA27500A1 (fr) 2005-08-01
AU2003296802A1 (en) 2004-08-10
KR20050084250A (ko) 2005-08-26
CO5700712A2 (es) 2006-11-30
HRP20050534A2 (en) 2006-11-30
NO20053341D0 (no) 2005-07-08
NO20053341L (no) 2005-09-07
NZ540496A (en) 2008-04-30
TW200503707A (en) 2005-02-01
CA2507945A1 (fr) 2004-07-29

Similar Documents

Publication Publication Date Title
EP1643986A4 (en) PHENYL ACARBOXYLATE BETA SECRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
EP1578253A4 (en) PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC DISEASE
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES
EP1656359A4 (en) MACROCYCLIC BETA-SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1651195A4 (en) PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1641748A4 (en) N-ALKYLPHENYLCARBOXAMIDE BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1604664A4 (en) MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
EP1490050A4 (en) METHOD FOR TREATING ALZHEIMER AND COGNITIVE IMPROVEMENT
EP1578385A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF INFLAMMATORY ENDURANCE DISEASES
EP1471874A4 (en) COMPOSITIONS AND METHODS OF TREATING WRINKLES, DELICACIES AND HYPERHIDROSIS
EP1910829A4 (en) PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGEN DISEASES
EP1771201A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-RELATED DISEASE
EP2166854A4 (en) TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
GB0223040D0 (en) Therapeutic compounds
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
EP1489915A4 (en) TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
EP1536804A4 (en) 2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
EP1628530A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING SEPSIS
EP1499333A4 (en) PROCESS FOR TREATING ILEUS
FR2860976B1 (fr) Nouvelles compositions synergiques pour ameliorer la biodisponibilite et l'efficacite des acides gras polyinsatures pour le traitement des troubles du fonctionnement cerebral.
FR2794369B1 (fr) Traitement de la maladie de peyronie
EP1745060A4 (en) COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE AND FOR INHIBITING BETA-AMYLOID PEPTIDE PRODUCTION
EP1575577A4 (en) COMPOSITION FOR THE AVOIDANCE AND TREATMENT OF EARLY SPIRITS

Legal Events

Date Code Title Description
RN Application for restoration
FC Decision of inpi director general to approve request for restoration
ST Notification of lapse

Effective date: 20090831